Medroxyprogesterone acetate and levonorgestrel increase genital mucosal permeability and enhance susceptibility to genital herpes simplex virus type 2 infection

Mucosal Immunology

Volumn 9, Issue 6, 2016, Pages 1571-1583

  Quispe Calla, N E ^a   Vicetti Miguel, R D ^a   Boyaka, P N ^b   Hall Stoodley, L ^a   Kaur, B ^c   Trout, W ^d   Pavelko, S D ^a   Cherpes, T L ^a,d  

^a Department of Microbial Infection and Immunity ^*  (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DESMOGLEIN 1; DESMOGLEIN 1 ALPHA; ESTROGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; ESTRUS CYCLE; FEMALE; GENE EXPRESSION REGULATION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN TISSUE; INFECTION RISK; INFLAMMATORY CELL; MEMBRANE PERMEABILITY; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; MICROBIOTA INVASION; MOUSE; NONHUMAN; NORMAL HUMAN; PREVALENCE; PRIORITY JOURNAL; PROTEIN FUNCTION; UTERINE CERVIX BIOPSY; VAGINA FLORA; VAGINAL MUCOSAL PERMEABILITY; ANIMAL; DISEASE MODEL; DRUG EFFECTS; GENITAL HERPES; IMMUNOLOGY; METABOLISM; MUCOSA; PERMEABILITY; VAGINA; VIROLOGY;

ANIMALS; CONTRACEPTIVE AGENTS, FEMALE; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; ESTROGENS; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MICE; MUCOUS MEMBRANE; PERMEABILITY; VAGINA;

EID: 84991687597     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.22     Document Type: Article

References (55)

1. Quinn, T.C., & Overbaugh, J. HIV/AIDS in women: an expanding epidemic. Science 308, 1582-1583 (2010
2. Morrison, C.S., et al. Hormonal contraceptive use, cervical ectopy, and the acquisition of cervical infections. Sex Transm. Dis. 31, 561-567 (2004
3. Baeten, J.M., et al. Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women. AIDS 21, 1771-1777 (2007
4. Morrison, C.S., et al. Hormonal contraception and HIV acquisition: reanalysis using marginal structural modeling. AIDS 24, 1778-1781 (2010
5. Heffron,R., et al. Partners in Prevention HSV/HIV Transmission Study Team. Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study. Lancet Infect. Dis. 12, 19-26 (2012
6. Warner, P. Concerns regarding design, analysis, and interpretation of the Morrison study on hormonal contraceptive use and acquisition of cervical infections. Sex Transm. Dis. 32, 644. author reply 645 (2005
7. Gray, R.H. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect. Dis. 12, 507 (2012
8. Hubacher, D. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect. Dis. 12, 508 (2012
9. Morrison, C.S., & Nanda, K. Hormonal contraception and HIV: an unanswered question. Lancet Infect. Dis. 12, 2-3 (2012
10. Ralph, L.J., McCoy, S.I., Hallett, T., & Padian, N. Next steps for research on hormonal contraception and HIV. Lancet 382, 1467-1469 (2013
11. Feldblum, P.J., et al. Randomized assignment to copper IUD or depotmedroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment. Contraception 72, 187-191 (2005
12. Stringer, E.M., et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am. J. Obstet. Gynecol. 197, 144.e1-e8 (2007
13. Shelton, J.D. Use of hormonal contraceptives and risk of HIV-1 transmission. Lancet Infect. Dis. 12, 507-508 (2012
14. McCoy, S.I., Ralph, L.J., Padian, N.S., & Minnis, A.M. Are hormonal contraceptive users more likely to misreport unprotected sex? Evidence from a biomarker validation study in Zimbabwe. AIDS Behav. 18, 2259-2264 (2014
15. Murphy, K., Irvin, S.C., & Herold, B.C. Research gaps in defining the biological link between HIV risk and hormonal contraception. Am. J. Reprod. Immunol. 72, 228-235 (2014
16. McNicholl, J.M., Henning, T.C., Vishwanathan, S.A., & Kersh, E.N. Non-human primate models of hormonal contraception and HIV. Am. J. Reprod. Immunol. 71, 513-522 (2014
17. Marx, P.A., et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084-1089 (1996
18. Khanna, K.V., et al. Vaginal transmission of cell-Associated HIV-1 in the mouse is blocked by a topical, membrane-modifying agent. J. Clin. Invest. 109, 205-211 (2002
19. Morrison, S.G., & Morrison, R.P. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J. Immunol. 175, 7536-7542 (2005
20. Roberts, J.N., et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat. Med. 13, 857-861 (2007
21. Whaley,K.J., Barratt, R.A., Zeitlin, L.,Hoen, T.E., & Cone, R.A. Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. J. Infect. Dis. 168, 1009-1011 (1993
22. Kaushic, C., Ashkar, A.A., Reid, L.A., & Rosenthal, K.L. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J. Virol. 77, 4558-4565 (2003
23. Yoo, J.Y., et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. Mol. Ther. 20, 287-297 (2012
24. Benagiano, G., Gabelnick, H., & Farris, M. Contraceptive devices: intravaginal and intrauterine delivery systems. Expert Rev. Med. Devices 5, 639-654 (2008
25. Africander, D., Verhoog, N., & Hapgood, J.P. Molecular mechanisms of steroid receptormediated actions by synthetic progestins used in HRTand contraception. Steroids 76, 636-652 (2011
26. Stanczyk, F.Z., Hapgood, J.P., Winer, S., & Mishell, D.R. Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endo. Rev. 34, 171-208 (2013
27. Kadmiel, M., & Cidlowski, J.A. Glucocorticoid receptor signaling in health and disease. Trends Pharmacol. Sci. 34, 518-530 (2013
28. Whaley, K.J., & Mayer, K.H. Strategies for preventing mucosal cellassociated HIV transmission. J. Infect. Dis. 15, S674-S680 (2014
29. Dinh, M.H., Okocha, E.A., Koons, A., Veazey, R.S., & Hope, T.J. Expression of structural proteins in human female and male genital epithelia and implications for sexually transmitted infections. Biol. Reprod. 86, 1-6 (2012
30. Blaskewicz, C.D., Pudney, J., & Anderson, D.J. Structure and function of intercellular junctions in human cervical and vaginal mucosal epithelia. Biol. Reprod. 85, 97-104 (2001
31. Green, K.J., & Simpson,C.L. Desmosomes: new perspectives on a classic. J. Invest. Dermatol. 127, 2499-2515 (2007
32. Sherrill, J.D., et al. Desmoglein-1 regulates esophageal epithelial barrier function and immune responses in eosinophilic esophagitis. Mucosal Immunol. 7, 718-729 (2014
33. Goldfien, G.A., et al. Progestin-containing contraceptives alter expression of host defense-related genes of the endometrium and cervix. Reprod. Sci. 22, 814-828 (2015
34. Deese, J., et al. Injectable progestin-only contraception is associated with increased levels of pro-inflammatory cytokines in the female genital tract. Am. J. Reprod. Immunol. 74, 357-367 (2015
35. Grabowski, M.K., et al. Use of injectable hormonal contraception and women's risk of herpes simplex virus type 2 acquisition: a prospective study of couples in Rakai, Uganda. Lancet Glob. Health 3, e478-e486 (2015
36. Carias, A.M., et al. Defining the interaction of HIV-1 with the mucosal barriers of the female reproductive tract. J. Virol. 87, 11388-11400 (2013
37. Sodora, D.L., Gettie, A., Miller, C.J., & Marx, P.A. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-Associated viral stocks. AIDS Res. Hum. Retroviruses 14, S119-S123 (1998
38. Mauck, C.K., et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception 60, 15-24 (1999
39. Bahamondes, L., et al. The effect upon the human vaginal histology of the long-term use of the injectable contraceptive Depo-Provera. Contraception 62, 23-27 (2000
40. Mitchell, C.M., et al. Long-term effect of depot medroxyprogesterone acetate on vaginal microbiota, epithelial thickness and HIV target cells. J. Infect. Dis. 210, 651-655 (2014
41. Chandra, N., et al. Depot medroxyprogesterone acetate increases immune cell numbers and activation markers in human vaginal mucosal tissues. AIDS Res. Hum. Retroviruses 29, 592-601 (2013
42. Sciaranghella, G., et al. CCR5 expression levels in HIV-uninfected women receiving hormonal contraception. J. Inf. Dis. 212, 1397-1401 (2015
43. Vicetti Miguel, R.D., et al. Dendritic cell activation and memory cell development are impaired among mice administered medroxyprogesterone acetate prior to mucosal herpes simplex virus type 1 infection. J. Immunol. 189, 3449-3461 (2012
44. Quispe Calla, N.E., Ghonime, M.G., Cherpes, T.L., & Vicetti Miguel, R.D. Medroxyprogesterone acetate impairs human dendritic cell activation and function. Hum. Reprod. 30, 1169-1177 (2015
45. Daniels, K., Daugherty, J., & Jones, J. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS Data Brief. 173, 2014
46. Committee on Adolescence. Contraception for adolescents. Pediatrics 134, e1244-e1256 (2014
47. Smith, P.J., et al. Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation 102, 2983-2989 (2000
48. Smith, S.M., et al. Topical estrogen protects against SIV vaginal transmission without evidence of systemic effect. AIDS 20, 1637-1643 (2009
49. Smith, S.M., Baskin, G.B., & Marx, P.A. Estrogen protects against vaginal transmission of simian immunodeficiency virus. J. Infect. Dis. 182, 708-715 (2000
50. Zhang, M., Xin, H., Duan, Y., & Atherton, S.S. Ocular reactivation of MCMV after immunosuppression of latently infected BALB/c mice. Invest. Ophthalmol. Vis. Sci. 46, 252-258 (2005
51. McLean, A.C., Valenzuela, N., Fai, S., & Bennett, S.A. Performing vaginal lavage, crystal violet staining, and vaginal cytological evaluation for mouse estrous cycle staging identification. J. Vis. Exp. 15, e4389 (2012
52. Cherpes, T.L., et al. Use of transcriptional profiling to delineate the initial response of mice to intravaginal herpes simplex virus type 2 infection. Viral Immunol. 26, 172-179 (2013
53. Schneider, C.A., Rasband, W.S., & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671-675 (2012
54. Eisenberg, E., & Levanon, E.Y. Human housekeeping genes, revisited. Trends Genet. 29, 569-574 (2013
55. Marill, K.A. Advanced statistics: linear regression, part I: simple linear regression. Acad. Emerg. Med. 11, 87-93 (2004